Opus Genetics, Inc. Common Stock
IRDOpus Genetics, Inc. is a biotechnology company focused on pioneering gene therapies and innovative treatments for genetic disorders. The company leverages advanced genomic technologies to develop targeted solutions aimed at improving patient outcomes and addressing unmet medical needs in the genetic medicine space.
Company News
Opus Genetics, a clinical-stage biopharmaceutical company, will present at the J.P. Morgan 2026 Healthcare Conference. The company focuses on developing gene therapies for inherited retinal diseases, with seven AAV-based programs targeting various genetic mutations.
Opus Genetics will present a corporate update at Chardan's 9th Annual Genetic Medicines Conference, highlighting their gene therapies for inherited retinal diseases and ongoing clinical trials for treatments like OPGx-LCA5 and OPGx-BEST1.
Opus Genetics reported promising results from a Phase 1/2 clinical trial of OPGx-LCA5, a gene therapy for Leber Congenital Amaurosis type 5, showing significant vision improvements in pediatric and adult participants with no serious adverse events.
Opus Genetics granted equity awards to its new Chief Financial Officer Rob Gagnon and five non-executive employees, including stock options and restricted stock units under the company's 2021 Inducement Plan.
Opus Genetics announced positive results from its LYNX-2 Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for treating vision disturbances in keratorefractive patients. The study met its primary endpoint, showing a significant improvement in mesopic low contrast distance visual acuity compared to placebo.
